Patient Education
Share your love
USC Receives $6M Grant for Dry AMD Therapy
The California Institute for Regenerative Medicine (CIRM) has awarded a $6 million, two-year grant to researchers at the USC Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute. This funding will advance preclinical studies…
Adverum Shares Positive Ixo-vec Results for Wet AMD
Adverum Biotechnologies has released promising 52-week topline results from its Phase 2 LUNA trial and new 4-year data from the Phase 1/2 OPTIC study for its gene therapy candidate Ixo-vec (AAV.7m8-aflibercept), targeting wet age-related macular degeneration (AMD). Transformative Potential of…
EO2002: Non-Surgical Solution for Corneal Edema
Emmecell has announced positive results from its U.S. multicenter Phase 1 trial evaluating EO2002, an innovative non-surgical cell therapy for corneal edema. The randomized, double-masked trial demonstrated significant improvements in best corrected visual acuity (BCVA) and reductions in central corneal…
Ophthalmology demand-capacity management in South East London through a single point of access (SPoA): a new model using NHS eRS | Eye – Nature
Ophthalmology demand-capacity management in South East London through a single point of access (SPoA): a new model using NHS eRS | Eye Nature Source: Author: | Date: 2024-11-21 08:00:00 Source: Author: | Date: 2024-11-21 08:00:00
Pilot and feasibility studies in ophthalmology: fundamental keys to success – Eye – Nature
Pilot and feasibility studies in ophthalmology: fundamental keys to success – Eye Nature Source: Author: | Date: 2024-11-21 08:00:00 Source: Author: | Date: 2024-11-21 08:00:00
Positive Phase 3 Results for MELT-300 Sedation
Melt Pharmaceuticals has reported promising topline results from the pivotal Phase 3 trial of MELT-300, a novel, non-intravenous, non-opioid sedation tablet developed for use during cataract surgeries. The study, conducted under an FDA-approved Special Protocol Assessment (SPA) agreement, demonstrated that…
Ocugen Shares Positive OCU410 Trial Results for GA
Ocugen has released encouraging preliminary findings from the Phase 1 portion of its Phase 1/2 OCU410 ArMaDa clinical trial, focused on treating geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The results demonstrate the potential of OCU410 as…
Strategies on How Reduce Eye Pressure Instantly
What Is Intraocular Pressure? Eye pressure, also known as intraocular pressure (IOP), is a critical factor in maintaining the health of your eyes. Elevated eye pressure can lead to various eye conditions, including glaucoma, which can result in permanent vision…
FDA Awards Designations to Gildeuretinol for Stargardt
Key Takeaways • Gildeuretinol (ALK-001) has received Rare Pediatric Disease and Fast Track designations, alongside prior Breakthrough Therapy and Orphan Drug statuses, emphasizing its potential to transform treatment for Stargardt disease. • Data from the TEASE-1…
Ray Tracing Optimization – Myopic LASIK & AI
Laser-assisted in situ keratomileusis (LASIK) has become one of the most effective and safe methods for correcting refractive error with laser corneal intervention, as evidenced by the long and large number of publications in the peer-reviewed literature. In recent years,…